Study Updated 03/28/2024

ClinicalTrials.gov#: NCT04919122
Study Design: Prospective Observational
PCORnet Infrastructure: Collaboration, CDM (+supplemental data), Engagement
Principal Investigator: Dan George
Site Name: Duke Clinical Research Institute
PCORnet® Network Partner: Coordinating Center
Funder: Exelixis, Bristol Myers Squibb, Merck, Pfizer
Funding Date: 2020
Study Duration: 2022 – 2026
Participating Clinical Research Networks: GPC, PaTH, REACHnet, STAR
Therapeutic Area: Oncology
Condition: Metastatic Renal Cell Carcinoma
Population: 19 Years and older (Adult, Older Adult)
Status: Recruiting

Research Question(s):

Can a research registry of patients with metastatic renal cell carcinoma (mRCC) patients help us better understand cancer management and health-related quality of life while receiving mRCC specific treatment? In combination with patient and physician surveys, PCORnet will be used to help us answer these questions.